Skip to content

A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)

A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030721
Enrollment
Unknown
Registered
2020-03-12
Start date
2020-03-16
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Gold Standard:Patients with mild or light COVID-19 confirmed by testing for novel coronavirus of the respiratory tract
Index test:1.&#32
swab 2.&#32

Sponsors

Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 15-79 years; 2. Patients with COVID-19 confirmed by testing for novel coronavirus of the respiratory tract;

Exclusion criteria

Exclusion criteria: 1. The patient has a history of alcohol or narcotic drug abuse, or a history of mental illness (such as schizophrenia, obsessive-compulsive disorder, depression), antagonistic personality, bad motivation, doubt, or other emotional or intellectual problems that may affect participation in this study The status of informed effectiveness; 2. Patients cannot cooperate with the relevant examinations of this project and do not agree with the informed consent form 3. The required information is incomplete; 4. pregnancy; 5. There are contraindications for sputum induction. Those who induce sputum by atomization may cause diseases, including: (1) Severe chest and lung diseases: such as acute asthma, acute exacerbation of COPD, pneumothorax, massive pleural effusion, acute or chronic respiratory failure; (2) a large amount of pericardial effusion; (3) cardiac function level III or above.

Design outcomes

Primary

MeasureTime frame
detection of SARS-CoV-2 RNA;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactHuanqin Han

Affiliated Hospital of Guangdong Medical University

huanqinhan@126.com+86 13828291023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026